On April 30, 2025, Immunic, Inc. announced the results from its phase 2 CALLIPER trial for vidofludimus calcium, a drug aimed at treating progressive multiple sclerosis, and shared details in a press release and corporate presentation. A live webinar about these results is scheduled for the same day.